Oxford Nanopore Technologies plc Share Price

Equities

ONT

GB00BP6S8Z30

Advanced Medical Equipment & Technology

Market Closed - London S.E. 16:35:28 17/06/2024 BST 5-day change 1st Jan Change
97.35 GBX -0.56% Intraday chart for Oxford Nanopore Technologies plc -4.18% -53.24%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 188M 239M 18.83B Sales 2025 * 242M 307M 24.18B Capitalization 845M 1.07B 84.47B
Net income 2024 * -150M -190M -15B Net income 2025 * -133M -169M -13.3B EV / Sales 2024 * 2.83 x
Net cash position 2024 * 311M 395M 31.11B Net cash position 2025 * 197M 249M 19.66B EV / Sales 2025 * 2.68 x
P/E ratio 2024 *
-5.73 x
P/E ratio 2025 *
-6.6 x
Employees 1,238
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.40%
1 week-4.18%
Current month-9.27%
1 month-10.03%
3 months-29.05%
6 months-49.82%
Current year-53.24%
More quotes
1 week
96.80
Extreme 96.8
105.50
1 month
96.80
Extreme 96.8
117.00
Current year
91.24
Extreme 91.243
212.59
1 year
91.24
Extreme 91.243
279.00
3 years
91.24
Extreme 91.243
736.00
5 years
91.24
Extreme 91.243
736.00
10 years
91.24
Extreme 91.243
736.00
More quotes
Managers TitleAgeSince
Founder - 31/12/04
Founder - 31/12/04
Director of Finance/CFO 42 01-21
Members of the board TitleAgeSince
Director/Board Member 66 23/06/21
Director/Board Member 58 12-18
Chairman 59 31/07/22
More insiders
Date Price Change Volume
17/06/24 97.35 -0.56% 1 483 915
14/06/24 97.9 -0.56% 1,033,837
13/06/24 98.45 -4.23% 516,656
12/06/24 102.8 -0.10% 603,759
11/06/24 102.9 +1.28% 511,095

Delayed Quote London S.E., June 17, 2024 at 04:35 pm

More quotes
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
0.979 GBP
Average target price
1.98 GBP
Spread / Average Target
+102.25%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW